Topic: BACE inhibitor

Biogen headquarters

2. Elenbecestat

Biogen and Eisai’s BACE inhibitor elenbecestat was the last drug in the class still standing when it finally hit the buffers in September, closing another chapter in the troubled story of amyloid-targeting drugs to treat Alzheimer’s disease.